Stijn L.W. Koolen

3.4k citations

155 papers · 2.3k indexed · 1 hit paper · h-index 25

Oncology top 2%
- Cancer Treatment and Pharmacology 28
- Cancer Immunotherapy and Biomarkers 20
- Pancreatic and Hepatic Oncology Research 16
- Colorectal Cancer Treatments and Studies 13
Pharmaceutical Science top 2%
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 25
Genetics top 5%
- Estrogen and related hormone effects 15
- Chronic Lymphocytic Leukemia Research 13
Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 12

Co-authors: Ron H.J. Mathijssen Jos H. Beijnen C. Louwrens Braal Agnes Jager Jan H.M. Schellens Alwin D. R. Huitema Esther Oomen‐de Hoop Elisabeth M. Jongbloed
Cited by: Oncology Pharmaceutical Science Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (8 papers)PLoS ONE (1 paper)The Lancet Oncology (1 paper)
Partner nations: Netherlands Switzerland United States

In The Last Decade

Stijn L.W. Koolen

146 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Stijn L.W. Koolen

Since Specialization

Citations

This map shows the geographic impact of Stijn L.W. Koolen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stijn L.W. Koolen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stijn L.W. Koolen more than expected).

Fields of papers citing papers by Stijn L.W. Koolen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stijn L.W. Koolen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stijn L.W. Koolen. The network helps show where Stijn L.W. Koolen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stijn L.W. Koolen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stijn L.W. Koolen Line = papers co-authored together Stijn L.W. Koolen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward Therapeutic Drug Monitoring ·Maud B. A. van der Kleij,Karolijn W. M. Groot Beumer,Stijn L.W. Koolen,Ron H.J. Mathijssen,Neeltje Steeghs,Alwin D. R. Huitema	2025	0
2	Drug release from docetaxel-entrapped core-crosslinked polymeric micelles: A population pharmacokinetic modelling approach based on clinical data Biomedicine & Pharmacotherapy ·Pascale C. S. Rietveld,Stijn L.W. Koolen,Stefan Zeiser,Cristianne J.F. Rijcken,Martijn van Noort,Ruben A.G. van Eerden,Florence Atrafi,Iris H.C. Miedema,C. Willemien Menke‐van der Houven van Oordt,Birgit C. P. Koch,Ron H.J. Mathijssen,Nelleke Snelder,Sebastiaan D. T. Sassen	2025	1
3	The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study EClinicalMedicine ·Niels A.D. Guchelaar,Micha J. de Neijs,Bo Jan Noordman,H. de Graaf,Irene E.G. van Hellemond,Pieter C. van der Sluis,Esther Oomen‐de Hoop,Sjoerd M. Lagarde,Rob H.A. Verhoeven,Stijn L.W. Koolen,Misha Luyer,Ignace H. J. T. de Hingh,Hanneke W.M. van Laarhoven,Bianca Mostert,Bas P. L. Wijnhoven,Ron H.J. Mathijssen	2025	1
4	Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis Biomedicine & Pharmacotherapy ·Bram C. Agema,M Berrich,L. Seuren,Sebastian D. T. Sassen,J.R. Miedema,Birgit C. P. Koch,Marlies Wijsenbeek,Stijn L.W. Koolen,Ron H.J. Mathijssen,G. Veerman	2024	0
5	Darolutamide does not interfere with OATP‐mediated uptake of docetaxel International Journal of Cancer ·Stefan A.J. Buck,Zahra Talebi,Thomas Drabison,Yan Jin,Alice A. Gibson,Peng Hu,Peter de Bruijn,Corrina M.A. de Ridder,Debra Stuurman,Shuiying Hu,Wytske M. van Weerden,Stijn L.W. Koolen,Ronald de Wit,Alex Sparreboom,Ron H.J. Mathijssen,Eric D. Eisenmann	2024	3
6	Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin CPT Pharmacometrics & Systems Pharmacology ·Pascale C. S. Rietveld,Sebastiaan D. T. Sassen,Niels A.D. Guchelaar,Ruben A.G. van Eerden,Nadine L. de Boer,Teun B M van den Heuvel,Jacobus W. A. Burger,Ron H.J. Mathijssen,Birgit C. P. Koch,Stijn L.W. Koolen	2024	2
7	Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis EBioMedicine ·Sophie M. Ernst,Maaike M. Hofman,Tessa E. van der Horst,Marthe S. Paats,Frank W J Heijboer,Joachim G.J.V. Aerts,Daphne W. Dumoulin,Robin Cornelissen,Jan H. von der Thüsen,Peter de Bruijn,Esther Oomen‐de Hoop,Ron H.J. Mathijssen,Stijn L.W. Koolen,Anne‐Marie C. Dingemans	2024	13
8	The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer ESMO Open ·Sanne M. Buijs,Esther Oomen‐de Hoop,C. Louwrens Braal,M.M. van Rosmalen,Jan C. Drooger,Quirine C. van Rossum‐Schornagel,Mijntje B. Vastbinder,Stijn L.W. Koolen,Agnes Jager,Ron H.J. Mathijssen	2023	10
9	Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition Molecular Cancer Therapeutics ·Stefan A.J. Buck,Annelies Van Hemelryk,Corrina de Ridder,Debra Stuurman,Sigrun Erkens‐Schulze,Sem van ’t Geloof,Wilma J. Teubel,Stijn L.W. Koolen,Elena S. Martens‐Uzunova,Martin E. van Royen,Ronald de Wit,Ron H.J. Mathijssen,Wytske M. van Weerden	2023	6
10	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Sebastiaan D. T. Sassen,Karlijn de Joode,Lisanne Putter,Edwin A. Basak,Annemarie Wijkhuijs,Markus Joerger,Reno Debets,Birgit C. P. Koch,Cor H. van der Leest,Marco W.J. Schreurs,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2021	15
11	Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma Pharmaceuticals ·Koen G. A. M. Hussaarts,Leni van Doorn,Sander Bins,Dave Sprengers,Peter de Bruijn,Roelof W. F. van Leeuwen,Stijn L.W. Koolen,Teun van Gelder,Ron H.J. Mathijssen	2021	8
12	The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients Pharmaceuticals ·Leni van Doorn,Marie‐Rose B. S. Crombag,Hánah N. Rier,Jeroen L.A. van Vugt,Charlotte van Kesteren,Sander Bins,Ron H.J. Mathijssen,Mark‐David Levin,Stijn L.W. Koolen	2021	5
13	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel Cancers ·Leni van Doorn,Mandy M van Rosmalen,Wendy M. van der Deure,Esther Oomen‐de Hoop,Robert Porrazzo,Sophie Wijngaard,Ingrid Boere,Paola Veenstra,Eman Ibrahim,Peter de Bruijn,Lena E. Friberg,Stijn L.W. Koolen,Ron H.J. Mathijssen,Agnes Jager	2021	2
14	Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC Pharmaceutics ·Eline Hooijman,Yozlem Chalashkan,Sui Wai Ling,Figen F. Kahyargil,Marcel Segbers,Frank Bruchertseifer,Aliyah Morgenstern,Yann Seimbille,Stijn L.W. Koolen,Tessa Brabander,Erik de Blois	2021	36
15	Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors Clinical Cancer Research ·Florence Atrafi,Ruben A.G. van Eerden,Marte A.M van Hylckama Vlieg,Esther Oomen‐de Hoop,Peter de Bruijn,Martijn P. Lolkema,Adriaan Moelker,Cristianne J.F. Rijcken,Rob Hanssen,Alex Sparreboom,Ferry A.L.M. Eskens,Ron H.J. Mathijssen,Stijn L.W. Koolen	2020	45
16	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach Clinical Pharmacology & Therapeutics ·Anna Mueller‐Schoell,Lena Klopp‐Schulze,Werner Schroth,Thomas E. Mürdter,Robin Michelet,Hiltrud Brauch,Wilhelm Huisinga,Markus Joerger,Patrick Neven,Stijn L.W. Koolen,Ron H.J. Mathijssen,Ellen Copson,Diana Eccles,Sylvia Chen,Balram Chowbay,Arafat Tfayli,Nathalie K. Zgheib,Matthias Schwab,Charlotte Kloft	2020	21
17	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib Pharmaceutics ·Koen G. A. M. Hussaarts,Leni van Doorn,Karel Eechoute,Jeffrey Damman,Qiang Fu,Nadia van Doorn,Eric D. Eisenmann,Alice A. Gibson,Esther Oomen‐de Hoop,Peter de Bruijn,Sharyn D. Baker,Stijn L.W. Koolen,Teun van Gelder,Roelof W. F. van Leeuwen,Ron H.J. Mathijssen,Alex Sparreboom,Sander Bins	2020	10
18	Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel? Pharmaceutical Research ·Marie‐Rose B. S. Crombag,Stijn L.W. Koolen,Sophie Wijngaard,Markus Joerger,Thomas P. C. Dorlo,Nielka P. van Erp,Ron H.J. Mathijssen,Jos H. Beijnen,Alwin D. R. Huitema	2019	5
19	Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer European Journal of Cancer ·Edwin A. Basak,Stijn L.W. Koolen,Daan P. Hurkmans,Marco W.J. Schreurs,Sander Bins,Esther Oomen‐de Hoop,Annemarie Wijkhuijs,Ilse den Besten,Stefan Sleijfer,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2019	54
20	Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer PLoS ONE ·Evelien Kuip,Wendy H. Oldenmenger,M.F. Thijs-Visser,Peter de Bruijn,Astrid W. Oosten,Esther Oomen‐de Hoop,Stijn L.W. Koolen,Carin C.D. van der Rijt,Ron H.J. Mathijssen	2018	4

About Stijn L.W. Koolen

Stijn L.W. Koolen is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 155 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (28 papers), Lung Cancer Treatments and Mutations (25 papers), Cancer Immunotherapy and Biomarkers (20 papers), Pancreatic and Hepatic Oncology Research (16 papers), Estrogen and related hormone effects (15 papers), Chronic Lymphocytic Leukemia Research (13 papers), Colorectal Cancer Treatments and Studies (13 papers) and Pharmacogenetics and Drug Metabolism (12 papers). The work is most often cited by research in Oncology (1.1k citations), Pharmaceutical Science (141 citations) and Pulmonary and Respiratory Medicine (755 citations). Stijn L.W. Koolen has collaborated with scholars based in Netherlands, Switzerland and United States. Frequent co-authors include Ron H.J. Mathijssen, Jos H. Beijnen, C. Louwrens Braal, Agnes Jager, Jan H.M. Schellens, Alwin D. R. Huitema, Esther Oomen‐de Hoop, Elisabeth M. Jongbloed, Saskia M. Wilting and Peter de Bruijn. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact